NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET FORECAST 2023-2032

The North America skin cancer diagnostics market growth evaluation covers an in-depth assessment of the United States and Canada. Skin cancer is the most prevalent form of cancer in the United States. As per the Skin Cancer Foundation, over 9,500 individuals are detected with skin cancer daily in the country, with over two patients dying of the condition every hour. Moreover, estimates also suggest that at least one in five Americans will likely develop skin cancer by the age of 70. The rates of melanoma have been surging rapidly over the last few decades in the United States. For example, according to the data issued by the American Cancer Society, in 2023, approximately 97,610 new melanomas are expected to be diagnosed in the country, including 39,490 in women as well as 58,120 in men. 

Additionally, the yearly expense of skin cancer treatment in the United States is estimated at more than $8 billion, with around $3.3 billion allocated for melanoma and about $4.8 billion for non-melanoma skin cancers. A strong presence of major companies operating in the skin cancer diagnostics market further indicates the remarkable potential for innovation as well as growth in the sector. These players are also expected to invest in research and development in order to improve existing diagnostic methods, while introducing novel technologies that facilitate accessibility, accuracy, and efficiency. Hence, such factors are anticipated to promote the skin cancer diagnostics market growth in North America during the forecasting years. 

The North America skin cancer diagnostics market is segmented into type, gender, and screening type. The screening type segment includes dermatoscopy, skin biopsy, lymph node, blood tests, and biopsy imaging tests. Melanoma, a rapidly spreading skin cancer type, tends to originally metastasize to a neighboring lymph node when it begins to spread. In this regard, a sentinel lymph node biopsy (SLNB) is performed to determine whether cancer cells have indefinitely spread to a lymph node in close proximity.

Furthermore, sentinel lymph node biopsy (SLNB) is conducted on patients who have already received a cancer diagnosis; the medical procedure entails the detection, removal, and subsequent inspection of the sentinel lymph node in order to examine the presence of cancer cells.

Some of the leading companies operating in the North America skin cancer diagnostics market include DermLite LLC, Castle Biosciences Inc, etc.

DermLite LLC, headquartered in the United States, is engaged in providing dermatoscopes as well as diagnostic tools. These solutions are intended to offer dermatologists an illuminated and magnified view of skin lesions. The company’s areas of specialization include Health Care Equipment and Medical Devices.

The DermLite DL1 Basic system helps primary care professionals to assess moles and skin lesions and send DermLite-quality images to specialists for review. The device also enables the early detection of skin cancer, in addition to other types of skin conditions.